Forbes J M & Co. LLP Grows Holdings in Zoetis Inc. (NYSE:ZTS)

Forbes J M & Co. LLP boosted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 0.2% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 54,710 shares of the company’s stock after purchasing an additional 111 shares during the period. Forbes J M & Co. LLP’s holdings in Zoetis were worth $8,914,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. State Street Corp increased its position in Zoetis by 0.5% in the 3rd quarter. State Street Corp now owns 19,779,344 shares of the company’s stock valued at $3,864,488,000 after acquiring an additional 95,856 shares during the period. Geode Capital Management LLC grew its stake in shares of Zoetis by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 10,427,760 shares of the company’s stock valued at $2,030,813,000 after purchasing an additional 185,364 shares during the last quarter. Mizuho Securities USA LLC increased its holdings in shares of Zoetis by 13,726.9% in the third quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company’s stock valued at $950,524,000 after purchasing an additional 4,829,815 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Zoetis by 5.3% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,896,106 shares of the company’s stock worth $761,221,000 after purchasing an additional 194,542 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its position in Zoetis by 10.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company’s stock valued at $569,834,000 after buying an additional 279,092 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Down 1.6 %

ZTS opened at $171.37 on Friday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The company has a market cap of $77.32 billion, a price-to-earnings ratio of 32.21, a PEG ratio of 2.77 and a beta of 0.90. Zoetis Inc. has a one year low of $144.80 and a one year high of $200.53. The business’s fifty day moving average is $169.26 and its two-hundred day moving average is $179.22.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.17%. Zoetis’s payout ratio is 37.59%.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Stifel Nicolaus cut their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Morgan Stanley cut their price target on shares of Zoetis from $248.00 to $243.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. UBS Group started coverage on Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective on the stock. JPMorgan Chase & Co. increased their target price on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Finally, Leerink Partners started coverage on Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target on the stock. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $215.00.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.